Lp(a) is one of the quieter cardiovascular risk markers: mostly inherited, usually symptomless, and absent from the standard cholesterol panel. The case for testing is getting stronger, but the interpretation is still clinical, not automatic. A high result can change a prevention conversation; it should not turn a blood test into a diagnosis or a self-directed treatment plan.
What Lp(a) measures
Lipoprotein(a), usually written as Lp(a), is an LDL-like particle with an extra apolipoprotein(a) component attached. That structure matters because it may contribute to atherosclerosis, inflammation, and clot-related risk in ways ordinary LDL cholesterol does not fully capture.
The American Heart Association describes Lp(a) as a cholesterol-carrying lipoprotein whose level is mostly inherited and whose elevation can increase the risk of heart disease and stroke. Its patient guidance also notes that high Lp(a) is common, usually silent, and only detected through a blood test ordered by a health professional: the American Heart Association’s Lp(a) overview.
That last point is the practical difference from many lifestyle markers. Someone can eat well, exercise, and have a conventional lipid panel that looks acceptable while still carrying elevated Lp(a). The result does not erase the value of those habits. It adds inherited risk information that may otherwise remain invisible.
Why one-time testing is being discussed more seriously
The most important shift is not that Lp(a) has suddenly been discovered. It has been studied for decades. The shift is that large genetic and epidemiological datasets have made the risk signal harder to dismiss, and professional groups now frame one-time measurement as a reasonable way to identify people whose usual risk score may understate lifetime risk.
A 2022 European Atherosclerosis Society consensus statement in the European Heart Journal concluded that Lp(a) has a role in atherosclerotic cardiovascular disease and aortic valve stenosis, and said Lp(a) should be measured at least once in adults, preferably with the first lipid profile: the 2022 EAS consensus statement. The AHA now gives similar public-facing advice, recommending at least one adult test.
This is not the same as annual screening. For most people, Lp(a) is genetically set enough that one well-performed measurement gives durable information. Repeat testing may be relevant if a result is borderline, a laboratory method changes, kidney or liver disease complicates interpretation, or a clinician is monitoring an intervention in a specialist setting.
A high result changes risk, not certainty
The most common mistake is to treat Lp(a) as a yes-or-no verdict. Cardiovascular risk does not work that way. Age, blood pressure, smoking, diabetes, kidney disease, ApoB or LDL cholesterol, family history, inflammatory disease, and imaging findings can all alter the meaning of one marker.
The AHA uses 125 nmol/L, or 50 mg/dL, as a level at which risk may increase, and notes that higher levels can carry greater risk. Those thresholds are helpful for orientation, but the units are not interchangeable in a simple way because Lp(a) particles vary in size. A result reported in nmol/L should not be casually converted into mg/dL with an internet calculator and treated as exact.
The National Heart, Lung, and Blood Institute gives the same broad picture: Lp(a) is inherited, elevated levels can increase cardiovascular risk, and people with high levels usually work with clinicians to manage overall risk factors rather than focusing on the number in isolation: NHLBI’s explanation of elevated Lp(a).
Family history is where the test becomes more than personal
Because Lp(a) is strongly inherited, a high result can matter for relatives. This is one reason Lp(a) sits partly in the biomarkers lane and partly in the genetics lane. It is not a full genetic test, but it can reveal a familial risk pattern that ordinary cholesterol screening misses.
The EAS statement recommends notifying close relatives and offering cascade testing when high Lp(a) is found, with counselling before and after testing. That is especially relevant when there is premature cardiovascular disease in a family, such as a heart attack or stroke before 55 in a man or before 65 in a woman.
Family testing needs careful handling. It can be useful, but it can also create anxiety if a result is handed over without context. A teenager with high Lp(a), a 45-year-old with high Lp(a) and high ApoB, and a 78-year-old with high Lp(a) but no clinical cardiovascular disease are not the same clinical problem. The number travels through families; the decision-making still belongs to individuals and their clinicians.
What can be done if Lp(a) is high
The unsatisfying answer is also the honest one: there is not yet an approved medicine whose primary job is to lower Lp(a) and prove better cardiovascular outcomes in routine care. Endotext, a peer-reviewed NCBI Bookshelf reference, states that there is currently no approved medication for lowering Lp(a) levels specifically, although some lipid-lowering treatments may have modest effects: Endotext’s Lp(a) chapter.
That does not make testing pointless. If Lp(a) is high, the usual response is to reduce the rest of the risk burden as precisely as possible: treat high LDL cholesterol or ApoB when indicated, control blood pressure, address diabetes or insulin resistance, stop smoking, manage kidney disease, and consider whether additional risk assessment, such as coronary artery calcium imaging, is appropriate for the individual.
This is where Lp(a) can be clinically useful without being directly treatable. A high inherited marker may lower the threshold for taking other risk factors seriously. It may also explain why a family has early cardiovascular events despite apparently ordinary cholesterol numbers. What it should not do is push someone into supplements, aspirin, niacin, or aggressive self-experimentation without medical advice.
New drugs are promising, but outcomes matter
Several RNA-based therapies designed to reduce Lp(a) are in clinical development, and some have produced large reductions in the biomarker. This is scientifically important. It is also the point where biomarker enthusiasm can outrun patient benefit.
Lowering Lp(a) is not automatically the same as preventing heart attacks, strokes, or aortic valve disease. Those outcomes require large, well-designed trials with enough follow-up to show whether changing the marker changes what matters clinically. Until those results are clear and regulators have reviewed safety and benefit, these drugs remain investigational rather than a reason to make consumer-facing promises.
The better interpretation is that Lp(a) is moving from an undermeasured risk marker toward a possible treatment target. That is a significant shift in cardiovascular prevention, but it is not a finished clinical story.
What this means in practice
- Ask about one-time Lp(a) testing if you have a personal or family history of premature cardiovascular disease, familial hypercholesterolaemia, or unexplained high risk despite ordinary cholesterol results.
- Check the units on the result. Nmoles per litre and milligrams per decilitre are reported differently and should be interpreted by the ordering clinician or lipid specialist.
- If Lp(a) is high, focus on the modifiable risks that can be treated now: ApoB or LDL cholesterol, blood pressure, smoking, diabetes, kidney disease, sleep apnoea, and physical inactivity.
- Discuss close-relative testing if your result is clearly elevated, especially when early heart disease or stroke appears in the family.
- Do not start aspirin, niacin, high-dose supplements, or lipid medicines solely because of an Lp(a) result without individual medical advice.
- Seek specialist input if Lp(a) is very high, cardiovascular disease occurred early in the family, or standard risk calculators do not seem to match the clinical picture.
What we don’t know
We do not yet know the best way to integrate Lp(a) into every prevention decision. Risk thresholds vary by guideline, laboratories report different units, and much of the strongest outcomes evidence comes from populations that may not fully represent every ancestry group or clinical setting.
We also do not yet know whether large Lp(a) reductions from new targeted drugs will translate into fewer cardiovascular events, fewer aortic valve procedures, or longer healthy life. The biology is compelling, but clinical medicine needs outcome data, not just cleaner blood-test numbers.
The sensible middle ground is to treat Lp(a) as inherited risk information with real value and real limits. One test may reveal something important. The result still has to be read alongside the person, the family history, and the risk factors that can be changed today.